08:00 , Nov 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Ixodes scapularis antifreeze glycoprotein (iafgp); poly-N-acetyl glucosamine (PNAG) Rodent, fruit fly and cell culture studies suggest iafgp derived from the I. scapularis...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

Sanofi (formerly sanofi-aventis Group) disclosed in its 3Q14 earnings that it and Alopexx agreed to terminate a 2009 deal under which Sanofi gained exclusive, worldwide rights to SAR279356 , which is being developed to treat...
07:00 , Jun 13, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection; candidiasis; malaria Poly-N-acetylglucosamine (PNAG) In vitro and mouse studies suggest an anti-PNAG antibody could help prevent infections from...
07:00 , Jun 13, 2013 |  BC Innovations  |  Targets & Mechanisms

PNAG: broadening infection protection

A multi-institutional team has added more than 20 pathogens to the list of known bacteria that express poly- N -acetylglucosamine, a bacterial capsule polysaccharide that provides a potentially broad-spectrum target for vaccination. 1 The findings...
07:00 , Apr 2, 2012 |  BioCentury  |  Emerging Company Profile

Arsanis: Antibodies for infection

By targeting conserved sequences of bacterial proteins as well as bacterial toxins, Arsanis Inc. expects its antibody cocktails to improve outcomes in infections that are resistant to conventional antibiotics. Arsanis was created when its three...
08:00 , Dec 14, 2009 |  BC Week In Review  |  Company News

Alopexx Pharmaceuticals, sanofi-aventis deal

Alopexx granted sanofi-aventis an option to license exclusive, worldwide rights to F598 . The mAb against poly-N-acetyl glucosamine (PNAG) is expected to begin Phase I testing next year to treat and prevent bacterial infections, including...
02:02 , Dec 11, 2009 |  BC Extra  |  Company News

sanofi receives option to Alopexx mAb

Alopexx Pharmaceuticals LLC (Cambridge, Mass.) granted sanofi-aventis Group (Euronext:SAN; NYSE:SNY) an option to license exclusive, worldwide rights to F598 . The mAb against poly-N-acetyl glucosamine (PNAG) is expected to begin Phase I testing next year...